首页|重构本草——决明子

重构本草——决明子

扫码查看
原文链接
  • 万方数据
  • 维普
通过古籍文献调研、中医药现代研究成果的梳理,结合中医临床及中药学等学科领域内知名专家学者的认识及应用经验,归纳出决明子:功效主要为清热明目,润肠通便.症靶为肥胖、便秘和目赤肿痛.标靶为血脂升高和血压升高.现代药理研究发现决明子及其有效成分具有降血压、降血脂、保护视网膜、通便、护肝、抗菌等作用.决明子主要化学成分大黄素型蒽醌类化合物具有肝肾毒性,临床使用中应注意用量配伍,以免造成或加重肝肾损伤.临床使用剂量为3～60 g,内服时当根据不同疾病,或同一疾病的不同阶段进行辨证使用,并积极探索决明子用量与症靶、标靶的量效关系构建.
Reconstruction of Chinese materia medica-cassia seed
Through the investigation of ancient books and the sorting of the modern research achievements of traditional Chinese medicine,combined with the understanding and application experience of well-known experts and scholars in desciplinary fields such as traditional Chinese medicine clinical medicine and science of Chinese materia medica,it is concluded that cassia seed mainly has the effects of clearing heat for improving eyesight,and smoothing intestine and relieving constipation.The symptom targets are obesity,constipation,and red eye and swelling and pain.The biochemical indicator targets are hyperlipidemia and hypertension.Modem pharmacological studies have found that cassia seed and its active ingredients have the effects of lowering blood pressure,lowering blood lipids,protecting the retina,defecating,protecting liver,and anti-bacteria and so on.The main chemical components in cassia seed,such as emodin type anthraquinone compounds,have hepatorenal toxicity.In clinical use,attention should be paid to dosage compatibility to avoid causing or aggravating liver and kidney damage.The clinical dose is 3-60 g.When taken orally,it should be used dialectically according to different diseases or different stages of the same disease,and the construction of dose-effect relationship between the dosage of cassia seed and the symptom target and biomeidical indicator target should be explored actively.

cassia seedsymptom targetbiochemical indicator targetreconstruction of Chinese materia medicaclinical verification

谢伟楠、段莹莹、刘珂、王昭博、赵锡艳、李丽静

展开 >

中国中医科学院广安门医院,北京 100053

北京中医药大学,北京 100029

西安交通大学第二附属医院,西安 710004

长春中医药大学药学院,长春 130117

展开 >

决明子 症靶 标靶 重构本草 临床回归

国家重点研发计划"中医药现代化"重点专项国家中医药管理局中医药创新团队及人才支持计划项目国家自然科学基金中央级公益性科研院所基本科研业务费专项资金中国中医科学院科技创新工程重大攻关项目中国中医科学院广安门医院临床医学研究中心建设专项经费中央高水平中医医院临床研究和成果转化能力提升项目传承名老中医药专家学术经验专项

2022YFC3502100ZYYCXTD-D-20200182205089ZZ13-YQ-030CI2021A016142022LYJSZX13HLCMHPP2023009

2024

10.13463/j.cnki.cczyy.2024.01.005

长春中医药大学学报
长春中医药大学

长春中医药大学学报

CSTPCD
影响因子：0.916
ISSN：1007-4813
年,卷(期)：2024.40(1)
  • 19